Empowering Precision Medicine

Cancer Genomics and Pharmacogenomics Testing

Our NGS-based solutions combine targeted panel testing and pharmacogenomics to deliver comprehensive insights for cancer care.

Our targeted panels identify key mutations associated with various cancers, supporting early detection, accurate diagnosis, and personalized treatment plans.

Additionally, our pharmacogenomics testing analyzes genetic variations that influence drug response, enabling clinicians to tailor therapies for maximum efficacy and minimal adverse effects.

Whole Exome Sequencing (Coming Soon)

Coming soon, Whole Exome Sequencing (WES) will analyze protein-coding regions of the genome to uncover actionable insights into cancer biology and rare genetic disorders, supporting advanced diagnostics and innovative treatment strategies.

Whole Genome Sequencing (Coming Soon)

Our upcoming Whole Genome Sequencing (WGS) service will provide a complete genomic profile, identifying novel biomarkers and unlocking new pathways for understanding complex diseases and guiding precision medicine.

Access to our state-of-the-art genomics lab facility.

Equipment includes RT-PCR, gradient PCR, touchdown PCR, and NGS sequencers.

Technical expertise in genomics, molecular biology, bioinformatics, and AI.

Genomics support for clinical trials, including biomarker discovery and validation.

Equipment includes RT-PCR, gradient PCR, touchdown PCR, and NGS sequencers.

Technical expertise in genomics, molecular biology, bioinformatics, and AI.

Molecular diagnostic services based on RT-PCR and NGS sequencing.

Rapid identification of pathogens and antimicrobial resistance markers